Infiltrated immune cells are an important constitute of tumor microenvironment, which exert complex effects on gastric cancer (GC) pathogenesis and progression. By using weighted gene co-expression network analysis, integrating the data from The Cancer Genome Atlas-stomach adenocarcinoma and GSE62254, we identify Aldo-Keto Reductase Family 1 Member B (AKR1B1) as a hub gene for immune regulation in GC. Notably, AKR1B1 is associated with higher immune infiltration and worse histologic grade of GC. In addition, AKR1B1 is an independent factor for predicting the survival rate of GC patients. In vitro experiments further demonstrated that AKR1B1-overexpressed THP-1-derived macrophages promoted the proliferation and migration of GC cells. Taken together, AKR1B1 plays an important role in GC progression by regulating immune microenvironment, which could be a biomarker for predicting GC prognosis as well as a potential therapeutic target for GC treatment.
Get full access to this article
View all access options for this article.
References
1.
BaillyC. Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer. Eur J Pharmacol, 2022; 931:175191; doi: 10.1016/j.ejphar.2022.175191
2.
BardouP, MarietteJ, EscudiéF, et al.jvenn: An interactive Venn diagram viewer. BMC Bioinform, 2014; 15(1):293; doi: 10.1186/1471-2105-15-293
3.
BarkleyD, MoncadaR, PourM, et al.Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat Genet, 2022; 54(8):1192–1201; doi: 10.1038/s41588-022-01141-9
4.
ChenL, ShiY, ZhuX, et al.IL-10 secreted by cancer-associated macrophages regulates proliferation and invasion in gastric cancer cells via c-Met/STAT3 signaling. Oncol Rep, 2019; 42(2):595–604; doi: 10.3892/or.2019.7206
5.
ChenY, YuanH, YuQ, et al.Bioinformatics analysis and structure of gastric cancer prognosis model based on lipid metabolism and immune microenvironment. Genes (Basel), 2022; 13(9):1581; doi: 10.3390/genes13091581
6.
ChenYT, ZhuF, LinWR, et al.The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. Cancer Chemother Pharmacol, 2016; 77(4):757–765; doi: 10.1007/s00280-016-2990-1
7.
CuiX, ZhangH, CaoA, et al.Cytokine TNF-α promotes invasion and metastasis of gastric cancer by down-regulating Pentraxin3. J Cancer, 2020; 11(7):1800–1807; doi: 10.7150/jca.39562
8.
DingY, WangZ, ChenC, et al.The gene regulatory molecule GLIS3 in gastric cancer as a prognostic marker and be involved in the immune infiltration mechanism. Front Oncol, 2023; 13:1091733; doi: 10.3389/fonc.2023.1091733
9.
FerroneC, DranoffG. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol, 2010; 28(26):4045–4051; doi: 10.1200/jco.2010.27.9992
10.
GabitassRF, AnnelsNE, StockenDD, et al.Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother, 2011; 60(10):1419–1430; doi: 10.1007/s00262-011-1028-0
11.
GretenFR, GrivennikovSI. Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity, 2019; 51(1):27–41; doi: 10.1016/j.immuni.2019.06.025
HuangQ, LanF, WangX, et al.IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer, 2014; 13:18; doi: 10.1186/1476-4598-13-18
14.
KhayamiR, HashemiSR, KerachianMA. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. J Cell Mol Med, 2020; 24(16):8890–8902; doi: 10.1111/jcmm.15581
15.
LangfelderP, HorvathS. WGCNA: An R package for weighted correlation network analysis. BMC Bioinform, 2008; 9:559; doi: 10.1186/1471-2105-9-559
16.
LeiZN, TengQX, TianQ, et al.Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther, 2022; 7(1):358; doi: 10.1038/s41392-022-01190-w
17.
LordickF, CarneiroF, CascinuS, et al.Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 2022; 33(10):1005–1020; doi: 10.1016/j.annonc.2022.07.004
18.
MaM, SunJ, LiuZ, et al.The immune microenvironment in gastric cancer: Prognostic prediction. Front Oncol, 2022; 12:836389; doi: 10.3389/fonc.2022.836389
NewmanAM, LiuCL, GreenMR, et al.Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 2015; 12(5):453–457; doi: 10.1038/nmeth.3337
21.
PanareseI, De VitaF, RonchiA, et al.Predictive biomarkers along gastric cancer pathogenetic pathways. Expert Rev Anticancer Ther, 2017; 17(5):417–425; doi: 10.1080/14737140.2017.1301207
22.
ParkD, 2nd, SonHJ, SongSY, et al.Role of TGF-beta 1 and TGF-beta type II receptor in gastric cancer. Korean J Intern Med, 2002; 17(3):160–166; doi: 10.3904/kjim.2002.17.3.160
PoorolajalJ, MoradiL, MohammadiY, et al.Risk factors for stomach cancer: A systematic review and meta-analysis. Epidemiol Health, 2020; 42:e2020004; doi: 10.4178/epih.e2020004
25.
ReddyKA, KumarPU, SrinivasuluM, et al.Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers. Breast, 2017; 31:137–143; doi: 10.1016/j.breast.2016.11.003
26.
SaraswathyR, AnandS, KunnumpurathSK, et al.Chromosomal aberrations and Exon 1 mutation in the AKR1B1 gene in patients with diabetic neuropathy. Ochsner J, 2014; 14(3):339–342.
27.
SogutluF, PekerbasM, Biray AvciC. Epigenetic signatures in gastric cancer: Current knowledge and future perspectives. Expert Rev Mol Diagn, 2022; 22(12):1063–1075; doi: 10.1080/14737159.2022.2159381
28.
SrivastavaSK, RamanaKV, BhatnagarA. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev, 2005; 26(3):380–392; doi: 10.1210/er.2004-0028
29.
TaskoparanB, SezaEG, DemirkolS, et al.Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer. Cell Oncol (Dordr), 2017; 40(6):563–578; doi: 10.1007/s13402-017-0351-7
30.
TibshiraniR. Regression shrinkage and selection via the lasso. J Royal Stat Soc Series B (Methodol), 1996; 58:267–288.
31.
TurleySJ, CremascoV, AstaritaJL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol, 2015; 15(11):669–682; doi: 10.1038/nri3902
32.
WangK, QiL, SunH, et al.Integrative analysis identifies a TNFα-derived gene signature for predicting prognosis, tumor immunity, and treatment sensitivity in gastric cancer. Front Genet, 2022a;13:882519; doi: 10.3389/fgene.2022.882519
33.
WangQ, TangY, WangT, et al.EPCR promotes MGC803 human gastric cancer cell tumor angiogenesis in vitro through activating ERK1/2 and AKT in a PAR1-dependent manner. Oncol Lett, 2018; 16(2):1565–1570; doi: 10.3892/ol.2018.8869
34.
WangZ, HanW, XueF, et al.Nationwide gastric cancer prevention in China, 2021–2035: A decision analysis on effect, affordability and cost-effectiveness optimisation. Gut, 2022b;71(12):2391–2400; doi: 10.1136/gutjnl-2021-325948
35.
XiaoMB, JinDD, JiaoYJ, et al.β2-AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway. Mol Biol Rep, 2018; 45(6):1863–1871; doi: 10.1007/s11033-018-4332-3
36.
YoshiharaK, ShahmoradgoliM, MartínezE, et al.Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun, 2013; 4:2612; doi: 10.1038/ncomms3612
37.
ZavrosY, MerchantJL. The immune microenvironment in gastric adenocarcinoma. Nat Rev Gastroenterol Hepatol, 2022; 19(7):451–467; doi: 10.1038/s41575-022-00591-0
38.
ZhangG, DongK, LiuJ, et al.Prognosis and tumor immune microenvironment of patients with gastric cancer by a novel senescence-related signature. Medicine (Baltimore), 2022; 101(40):e30927; doi: 10.1097/md.0000000000030927
39.
ZhaoJ, ZhaoY, DingS, et al.Low CBS expression can identify patients who benefit from adjuvant chemotherapy in gastric cancer. Expert Rev Anticancer Ther, 2021; 21(11):1287–1298; doi: 10.1080/14737140.2021.1962298
40.
ZhaoW, LinJ, ChengS, et al.Comprehensive analysis of COMMD10 as a novel prognostic biomarker for gastric cancer. PeerJ, 2023; 11:e14645; doi: 10.7717/peerj.14645
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
